Draft Misuse of Drugs Act 1971 (Amendment) Order 2022

Naz Shah Excerpts

Thursday 27th January 2022 General Committees

[Naz Shah (Bradford West) (Lab)]

It is a pleasure to serve under your chairmanship, Mr Hollobone. I thank the Minister for his remarks. The Opposition supports the proposals in this statutory instrument, which will introduce restrictions around the drug GHB and related substances by moving them from class C to class B, following recommendations by the independent Advisory Council on the Misuse of Drugs. The instrument will also bring forward measures on two substances—GBL and 1,4-butanediol—that can be converted to GHB on ingestion, as the Minister suggested, so that those wishing to possess them for legitimate industrial purposes will require a licence. GHB causes profound unconsciousness and has been used to facilitate some appalling crimes, such as those committed by Stephen Port, who used GHB to incapacitate his victims, and Reynhard Sinaga, who was found guilty of 136 counts of rape.

We are committed to working with the Government, the police and other public bodies to tackle drug misuse, strengthen controls on dangerous substances and widen the availability of treatments to prevent overdose deaths and get drug users clean. Clearly, where drugs cause harm, they must be classified and enforcement action must be taken to better protect victims from criminal abuse. In recent years, GHBRS have been used by prolific serial rapists, but rapists are more likely to get away with their crimes than to be prosecuted. The Government should be working much harder to reduce the prevalence of sexual violence and improve the shockingly low charge rate for rape. I have to remind the Minister of the context of the statutory instrument—that rapists are getting away with it—to show that this welcome change is just one part of the solution.

The impact assessment for the statutory instrument states that

“statistical experiments cannot conclusively state whether reclassification causes an increase or decrease in consumption/prevalence of a drug. The evidence base for the effects of reclassification is mixed.”

Can the Minister set out how he expects the reclassification to decrease the prevalence of GHB? We absolutely support the change to reschedule GBL and 1,4-BD from a bespoke status to schedule 1. The impact assessment tells us that the change

“will correspond to a reduction in the supply of these drugs because, in practice, the current legislation allows for unimpeded access to these drugs via the clear web.”

Does the Minister have any plans to tackle the sale of GHBRS on the dark web?

According to the Office for National Statistics, between 2008 and 2017 there were, on average, 19 deaths related to GHB per year. The ACMD tells us:

“There is evidence of increasing mortality associated with GHBRS use”,

and:

“Although the overall number of deaths is relatively low there was a steep rise in deaths between 2008 and 2015…However, mortality figures are likely to be an underestimate due to the challenges in testing for and identifying GHBRS in post-mortem samples”.

That makes it hard to make pronouncements in criminal cases, as does the fact that victims sometimes do not remember that they have been the victim of a crime, or they remember very little about it.

The withdrawal symptoms of GHBRS are severe and can be life-threatening, with high relapse rates. The ACMD says that

“more research is needed to investigate effective clinical management of withdrawal, and effective relapse prevention.”

Survivors of a drug-facilitated sexual assault will experience a complex combination of harms and require support from various different services. There are concerns that the reclassification may make people less likely to ask for help or for an ambulance. I ask the Minister for some assurances about those who purchase GHB to use consensually, many of whom are LGBTQ+. How will their safety be ensured? The ACMD report states that

“there is significant evidence of stigma experienced by LGBT GHBRS users, which is a barrier to service access. The complex harms—both physical, mental and social—experienced by MSM require specialist sexual assault support, and it is reported that users believe that current services do not meet these needs.”

Will the Government introduce any increased harm reduction services or victim support alongside the measures in the statutory instrument?

As the Minister will know, the ACMD made eight recommendations in its report. Some are reflected in the SI, but some really important recommendations are not reflected. Clearly, the control of substances and drugs is extremely important, but people’s safety and the reduction of harm will not be addressed by tighter controls alone. As the report’s recommendations suggest, better data collection and reporting of GHBRS use is vital. We need more routine testing for it in cases of unexplained sudden death, better integration of drug treatment and sexual health services, and better education for frontline staff in the health and social care system who come into contact with GHBRS users, as well as improved treatment interventions and more information and support for those at the highest risk of harms associated with GHBRS. Will the Minister set out the Government’s response to the other recommendations in the ACMD report?

We welcome the statutory instrument. It is absolutely right to update the controls and classification of drugs that are dangerous and that are sometimes used for sickening sexual crimes, but we must also acknowledge that this is a small part of what is needed. So much more needs to be done to reduce the prevalence of these crimes, to increase prosecutions for rape and to tackle the perpetrators of sexual violence. We all know the terrible impact that drugs can have on individuals, families and communities. Increasing enforcement of drug misuse, and stamping out the organised criminals and drug gangs that profit from it, is incredibly important, but it is one part of the solution. The other part must be drug treatment and preventive services, in order to properly break the cycle of drug misuse.